CPT 93623Cardiology

Prgrmd stimj&pacg iv rx nfs

CPT code 93623 covers programmed electrical stimulation and pacing of the heart performed after giving medication through an IV to evaluate heart rhythm abnormalities. This is an add-on test that cardiologists use to see how the heart responds to drugs during electrophysiology studies.

Showing rates for

National Average

Base Medicare rate

$51.75

This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.

RVU breakdown

Work RVU

0.98

PE RVU (NF)

0.44

MP RVU

0.18

Total RVU

1.6

Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High

NCCI bundling edits

Loading bundling edits…

Billing tips

Always bill 93623 as an add-on code with a primary EP study code (93619, 93620, or 93653-93656); it cannot be billed standalone
Impact: Billing without primary code results in 100% denial; proper pairing ensures $51.75 reimbursement
Document specific drug name, dose, route, timing of infusion, and wait time before post-drug pacing protocols in procedure note
Impact: Inadequate drug documentation is leading cause of medical necessity denials; complete documentation reduces denial rate by approximately 35%
Report only once per session regardless of number of drugs administered or pacing protocols performed after drug infusion
Impact: Reporting multiple units results in downcoding to one unit; this is a per-session code with maximum payment of $51.75
Verify that pacing protocols performed after drug differ from baseline protocols and document clinical rationale for drug administration
Impact: Payers may deny if post-drug testing appears duplicative; clear differentiation supports medical necessity and prevents recoupment
For Brugada syndrome evaluation with sodium channel blocker challenge, include ICD-10 code I49.8 and document family history or symptoms supporting testing
Impact: Enhanced documentation for genetic arrhythmia syndromes reduces initial denial rate by approximately 25% for this high-scrutiny indication
Submit claims within 30 days of service date and ensure facility and professional claims align on date, codes, and medical necessity
Impact: Timely filing and claim alignment reduces payment delays averaging 45-60 days and prevents split denials between facility and professional components

Live Field Datano reports yet

Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.

Working with CPT 93623?

Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.

Help build the field knowledge

MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.

Related actions

Frequently asked questions

What is the Medicare reimbursement rate for CPT code 93623 in 2025?

The 2025 Medicare national average payment for CPT 93623 is $51.75 for both facility and non-facility settings. This is based on a total RVU of 1.6 (Work RVU 0.98, PE RVU 0.44, MP RVU 0.18) multiplied by the 2025 conversion factor of 32.3465.

Can CPT 93623 be billed alone or does it require a primary code?

CPT 93623 is an add-on code and cannot be billed alone. It must be reported with a primary comprehensive electrophysiologic evaluation code such as 93619, 93620, or 93653-93656. Billing 93623 without a primary EP study code will result in denial.

How many times can CPT 93623 be reported during a single EP study session?

CPT 93623 should be reported only once per session regardless of the number of drugs administered or the number of post-drug pacing protocols performed. Medicare and most payers will downcode multiple units to a single unit per date of service.

What drugs are typically administered when billing CPT 93623?

Common medications include antiarrhythmic drugs (procainamide, flecainide, sotalol, amiodarone), isoproterenol for catecholamine-sensitive arrhythmias, adenosine for certain tachycardias, or sodium channel blockers (ajmaline, procainamide) for Brugada syndrome provocation testing. The specific drug, dose, and clinical indication must be documented.

What is the difference between CPT 93623 and the primary EP study codes?

Primary EP study codes (93619-93620, 93653-93656) cover baseline comprehensive electrophysiologic evaluation including initial stimulation and pacing. CPT 93623 represents the additional work of administering IV medication and performing subsequent programmed stimulation protocols to assess drug effects on cardiac electrophysiology.

Does CPT 93623 include both the professional and technical components?

Yes, CPT 93623 is a global code that includes both professional and technical components. However, the 2025 Medicare rate is identical ($51.75) for both facility and non-facility settings, indicating minimal PE differential. Modifier 26 would only apply in settings where component billing is specifically required by payer policy.

What documentation is required to support medical necessity for CPT 93623?

Required documentation includes the clinical indication for pharmacologic testing (such as assessing antiarrhythmic drug efficacy, provocative testing for suspected genetic arrhythmia syndromes, or evaluating drug effects on inducibility), the specific drug administered with dose and timing, wait period after infusion, detailed post-drug pacing protocols performed, and comparison of baseline versus post-drug electrophysiologic findings.